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Recent advances in induced pluripotent stem cell technologies and phenotypic screening shape the future of
bioactive small-molecule discovery. In this review we analyze the impact of small-molecule phenotypic
screens on drug discovery as well as on the investigation of human development and disease biology. We
further examine the role of 3D spheroid/organoid structures, microfluidic systems, and miniaturized on-a-
chip systems for future discovery strategies. In highlighting representative examples, we analyze how recent
achievements can translate into future therapies. Finally, we discuss remaining challenges that need to be
overcome for the adaptation of the next generation of screening approaches.Introduction
Phenotypic screening (PTS) has experienced a renaissance,
promising high-throughput access to more complex disease
models and unknown disease mechanisms. Combining
increased sophistication in high-throughput automation, cell cul-
ture, molecular engineering, and hardware and software for data
analysis with patient-derived induced pluripotent stem cell
(iPSC) strategies has opened up entirely new opportunities for
modeling diseases in vitro. In addition to addressing conven-
tional therapies focusing on cellular misregulation, PTS can iden-
tify new compounds and protocols to drive targeted cell fate
switching within tissues. This may allow combating tissue dam-
age including aging and degenerative diseases through induc-
tion of local tissue repair via activation/generation of tissue-
resident precursor cells, which, in turn, replenish somatic cell
populations lost due to injury or disease. However, control of
increasingly complex biology requires the codevelopment of a
number of upstream and downstream technologies to enable
the generation of more homogeneous and closely defined
iPSC-derived tissue models in 2D and 3D cultures, to efficiently
gather and interpret multidimensional data, and to close the gap
between in vitro and in vivo disease biology.
We highlight examples for the broad utility of PTS approaches
in combination with pluripotent stem cell technologies in a vari-
ety of established fields including toxicity testing, disease
modeling, and conventional 2D high-throughput screening
(HTS). We place a significant focus on new and developing tech-
nologies that enable modeling and control of tissue andmultifac-
torial disease complexity in vitro. Thus, we evaluate the current
state of 3D cell culture, organs-on-a-chip, as well as the increas-
ingly complex challenges of data analysis in view of their use in
HTS workflows. Further key developments in the future of HTS
will hinge on converging the disparate fields of cell culture auto-
mation, microfluidics, organic chemistry and library design, re-porter systems biology, high-content analysis, data mining,
and machine learning. We examine examples of each of these
fields in turn as far as they demonstrate relevance to key aspects
of future HTS strategies.
Background
Successful drug discovery campaigns often employ one of two
general hit identification strategies: target-based screening
(TBS) or PTS (Eder et al., 2014; Swinney and Anthony, 2011).
TBS identifies small molecules or biologics (large bioactive mole-
cules such as antibodies, nucleic acids, and so forth) that can
modulate the biological activity of a known molecular disease
target. Target-based approaches first identify molecular targets
and then find and optimize drug candidates that specifically
engage their targets in cell-based, biophysical, and/or biochem-
ical assays in vitro. This is followed by subsequent validation of hit
molecules in complementing bioassays as well as by functional
profiling in vivo. In contrast, PTS measures the functional conse-
quences (i.e., the phenotype) of drug candidates in the context of
a disease-relevant cell type or organism, irrespective of the mo-
lecular target and mechanism involved. PTS mostly employs
cell-based assay formats, which ideally serve as safety and dis-
ease models by approximating a particular pathophysiology.
Before 1970, most drugs were discovered by PTS (Pina et al.,
2009). However, advances in bioassay technologies, miniaturiza-
tion, workflow automation, as well as a steep increase in putative
drug targets, enabled TBS of large libraries in HTS campaigns
(Drews, 1996; Rask-Andersen et al., 2011). This reductionist
approach of breaking complex diseases down into molecular
drug targets led to a dramatic increase in the number of drug can-
didates (Imming et al., 2006; Pereira and Williams, 2007). Howev-
er, TBS fell short of meeting initial expectations for increased
numbers of market-approved therapeutics (Harrison, 2016; Over-
ington et al., 2006; Scannell et al., 2012; Swinney and Anthony,Cell Chemical Biology 26, August 15, 2019 ª 2019 Elsevier Ltd. 1
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the origin of disease, it became apparent that many diseases
have multifactorial origins and are thus only inadequately repre-
sented in single TBS approaches (Gregori-Puigjane et al., 2012).
Further ‘‘-omics’’ analyses and genome-wide association studies
(GWASs) revealed that the ‘‘one-drug-one-target’’ reductionist
approach of TBS often does not capture the complexity of dis-
eases (Mestres et al., 2009; Sams-Dodd, 2013). By using stan-
dardized cell lines, TBS biology often lacks cell-type-specific
signaling pathways or posttranslational modifications along with
otherproperties inherent to thediseasedcell types.Consequently,
drugcandidates identifiedbyTBS frequently failed todemonstrate
efficacy or safety in clinical trials (Mestres et al., 2009).
These shortcomings of target-based drug discovery have led
to a renewed interest in PTS approaches (Eggert, 2013; Haasen
et al., 2017; Lee and Berg, 2013; Vincent et al., 2015). Ideally,
phenotypic assays measure endogenous, physiological re-
sponses of disease-relevant cell types. Therefore, they poten-
tially represent a more appropriate approximation of disease-
relevant physiology than isolated biochemical reactions. PTS
can also help identify disease mechanisms and novel drug tar-
gets that can be later pursued with established, highly evolved
TBSworkflows (Swinney, 2014). However, a significant limitation
of PTS strategies is that the drug target andmechanism of action
need to be determined separately in a target deconvolution pro-
cess. Although knowledge about mechanism of action is not
mandatory for drug approval, it is highly desirable for vetting
drug candidates for stability, potential adverse effects, and
possible delivery options before entry into clinical trials.
Despite considerable progress, PTS and TBS often share one
conceptual challenge: the highly streamlined assay biology may
fail to recapitulate signaling pathways and physiological traits of
disease-relevant cell types in vivo, and assay results may not
translate well into human clinical outcomes (Horvath et al.,
2016). Although PTS is frequently considered superior to TBS
in capturing disease biology, the tissue culture conditions for
PTS assays differ markedly from the physiological environment
of the diseased tissue, where cells interact and communicate
with each other and with the extracellular matrix. Standard assay
conditions in 2D adherent tissue culture bear little resemblance
to physiological conditions but have been necessary to enable
automated HTS workflows. Finally, cell lines used in PTS cam-
paigns rarely originate from patients and thus lack the disease-
specific genetic background.
Stem Cells Open up New Opportunities for Disease
Modeling and Toxicity Screening
PTS using human induced pluripotent stem cell (hiPSC) technol-
ogies can address some of these shortcomings. hiPSCs can (1)
be differentiated into disease-relevant cell types, (2) form hetero-
geneous cell cultures that can more closely mimic the cellular di-
versity of human tissues, (3) be generated from patient-derived
tissues that bear the hallmarks of genetic and epigenetic disease
states, (4) enable 3D culture to emulate tissue-like environments,
and (5) populate microfluidic devices (organ-on-a-chip) (Chen
et al., 2018). Advances in iPSC technologies have improved sup-
ply of stem cells and have led to the establishment of robust,
xeno-free protocols (Chen et al., 2011; Ebert and Svendsen,
2010; Frank et al., 2012; Gunaseeli et al., 2010; Shi et al., 2017)2 Cell Chemical Biology 26, August 15, 2019for differentiation of hiPSCs into many human cell types that
can serve as disease models and are suitable for drug discovery
(Heilker et al., 2014; Takahashi and Yamanaka, 2016). hiPSCs
are readily accessible and can be generated easily from many
somatic tissues in using commercial solutions. iPSC reprogram-
ming technologies can thus provide cells for HTS campaigns that
are otherwise unavailable because primary cells derived from
patients are postmitotic and do not proliferate to generate suffi-
cient quantities (i.e., human neurons). In addition, iPSC technol-
ogies facilitate genetic modification that may be difficult to
achieve in many primary cell types (i.e., hepatocytes). Genome
engineering tools such as zinc-finger nucleases, CRISPR-Cas,
or transcription activator-like effector nucleases (TALENs) can
be used to address genetic variance and generate appropriate
isogenic control cell lines for drug discovery in order to conduct
HTS campaigns using cell lines with identical genetic back-
ground (Chang et al., 2018). This approach will minimize interin-
dividual differences and enable the identification of novel com-
pounds, the discovery of which would have been obscured by
genetic variation between nonisogenic cell lines. Furthermore,
stem cell databases and repositories, such as HPSCreg.eu,
EBiSC, the UK Stem Cell Bank, the International Stem Cell Reg-
istry, and Cellular Dynamics International, will offer additional
standardization and quality control.
Advances of Stem Cell-Based PTS in 2D Cultures
Building on the strengths and relative maturity of adherent stem
cell protocols, several PTS have provided proof-of-concept for
iPSC-driven screening approaches (Kondo et al., 2017; Ster-
neckert et al., 2014) (also summarized in Table 1). At the same
time, these approaches highlight the importance of careful hit
validation strategies.
Combining PTS with GWASs can establish links between ge-
netic variants and disease traits across a population. CRISPR-
Cas9 gene editing was used to generate human isogenic pancre-
atic beta-like cells that carry biallelic null mutations in susceptible
genes, such as CDKAL1, which were associated with type 2 dia-
betes mellitus in GWASs (Zeng et al., 2016) (Figure 1A). The study
revealed that susceptible genes modulate proper function and
survival of pancreatic beta cells. The generated CDKAL1/ hu-
man cell population exhibited insulin secretion impairment
in vitro and showed defective glucose homeostasis in a mouse
model. Moreover, the CDKAL1/ cells were hypersensitive to
glucotoxicity and lipotoxicity. Screening 2,000 US Food and
Drug Administration (FDA)-approved drugs by measuring the
number of insulin-containing cells using an insulin-specific anti-
body yielded compound T5224 as a hit. This inhibitor of FOS/
JUN activator protein-1 (AP-1) was found to protect cells against
induced glucolipotoxicity in a dose-dependent manner and
rescue CDKAL1-associated defects both in vitro and in vivo by in-
hibiting the FOS/JUN pathway. Oral administration of T5224 or
transplantation of CDKAL1/ cells with RNAi-mediated loss of
FOS rescued pancreatic beta cell dysfunction in an in vivomouse
model. These findings suggest that FOS/JUN inhibition via phar-
macologic or genetic intervention may represent an attractive
therapeutic option for patients carrying the CDKAL1/ risk allele.
Combining a high-content-based screen for the expression of
fragile X mental retardation (Fmr1) protein with iPSC-derived hu-
man neural precursor cultures, a group at Novartis screened
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FMRP, fragile X mental retardation protein; IPF, idiopathic pulmonary fibrosis; Ki-67, FHA domain-interacting nucleolar phosphoprotein; LOPAC,
Library of Pharmacologically Active Compounds; N/A, not applicable; PI, propidium iodide; proSP-C, prosurfactant protein-C; Tau, microtubule-
associated protein tau; TUJ1, neuron-specific class III b-tubulin.
aDepending on the type of analysis algorithm.
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abnormal silencing of the Fmr1 gene (Kaufmann et al., 2015)
(Figure 1B). A multiparametric, machine-learning-based image
analysis yielded hit rates between 1.1% and 2.8%, depending
on the type of analysis algorithm. These efforts highlight the
potential of iPSC-derived PTS to identify modulators of epige-
netic misregulation.
TALEN-mediated genetic engineering was used to generate
hiPSCs that inducibly express Neurogenin 2 to ultimately
generate hiPSC-derived postmitotic neurons with high efficiency
and homogeneity (Wang et al., 2017) (Figure 1C). These neurons
were used to search for small molecules that can reduce thelevels of human Tau protein. High-throughput-screening of the
Library of Pharmacologically Active Compounds on these i3N
neurons identified moxonidine and metaproterenol as hits. Both
molecules are adrenergic receptor (AR) agonists, suggesting
that AR signaling is associated with Tau homeostasis. This study
identified AR activation as a potential therapeutic approach for
the treatment of tauopathies by lowering Tau levels.
AstraZeneca performed a phenotypic screenwith adult human
primary epicardium-derived cells (EPDCs) to identify small mol-
ecules that can activate the endogenous regenerative capacity
of cardiac progenitor cells and thus restore the heart’s limited






(legend on next page)
4 Cell Chemical Biology 26, August 15, 2019
Cell Chemical Biology
Review




Please cite this article in press as: Friese et al., The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery, Cell Chemical Biology
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mainly to two distinct chemotypes with disparate biological ac-
tivities. Chemotype 1 activated proliferation in both EPDCs and
cardiac fibroblast cells, the latter of which served as a control.
On the other hand, a different compound representing chemo-
type 2 selectively activated proliferation only in EPDCs. These
findings emphasize the importance of appropriate triaging of
hit molecules obtained by PTS. Evaluation of previously reported
biological targets of both compounds did not reproduce
this phenotype. However, target deconvolution approaches
employing in vitro kinome profiling and functional evaluation of
additional 147 biological targets revealed a rather promiscuous
activity profile for chemotype 1. This result suggested that its
mode of action might involve polypharmacology. In contrast,
chemotype 2 showed no significant activity on additional targets
within this same panel, suggesting that it is less prone to off-
target effects.
Another example describing the challenges of hit validation
following a phenotypic screen was reported by GlaxoSmithKline
(Billin et al., 2016) (Figure 1E). Enhancing proliferation of skeletal
muscle progenitor stem cells (satellite cells), which generate new
skeletal muscle upon injury, can be a therapeutic approach to
treat acute and/or age-associated muscle loss. This approach
used aged murine cells to screen 800 target-annotated com-
pounds and found that GK2226649A, an inhibitor of c-Jun N-ter-
minal kinase 1 (JNK-1), can restore the proliferative capacity of
satellite cells. This hit was confirmed in vivo using a contrac-
tion-induced muscle-damage mouse model. However, struc-
ture-activity relationship studies could not establish a functional
connection between JNK-1 inhibition (target) and satellite cell
proliferation (phenotype). Neither kinome profiling in vitro nor
chemical proteomics experiments in HeLa and muscle-derived
A204 rhabdomyosarcoma cell lysates revealed any other tar-
gets. These findings further underscore the importance of appro-
priate, and, ideally, human cell models for compound screening
and validation that can capture key differences between animal
and human physiology.
PTS was recently used to identify compounds with activity
against idiopathic pulmonary fibrosis, a severe lung disease
characterized by progressive lung dysfunction due to alteration
of the alveolar epithelial barrier of epithelial cells in the respiratory
system (Fujino et al., 2017) (Figure 1F). The increase in levels of
prosurfactant protein-C, a marker specific to alveolar epithelial
type II cells, was used to monitor the response of mesenchymal
lung-like stem cells from adult human patients after addition of
inhibitors from a kinase-focused compound library. Target de-
convolution using kinase profiling identified a single hit, 2D08,
an inhibitor of the receptor tyrosine kinase Axl as a potential
target, which was confirmed by small interfering RNA loss-of-
function analysis. Further investigations revealed that pharma-
cological or genetic reduction of Axl kinase activity led to fewer
mesenchymal traits in the starting cell population, leading to
increased cell adhesion. As Axl activation was observed inFigure 1. Graphical Representation of the Examples Mentioned in the
Toxicity Screening’’ Section
Abbreviations: AP-1, FOS/JUN activator protein-1; CDKAL1, CDK5 regulatory sub
content screening; hESC, human embryonic stem cell; hiPSC, human induced p
ProSP-C, prosurfactant protein-C; TALEN, transcription activator-like effector nulung regions with a compromised epithelial barrier, this study re-
vealed a novel opportunity for improving lung function by Axl
inhibition in the treatment of idiopathic pulmonary fibrosis.
Stem Cell-Based Phenotypic Toxicity Screens
Adherent iPSC-based PTS are ideally suited to form the basis for
more sensitive and physiologically relevant toxicity screens for
human tissues. A major cause for phase I clinical trial failure of
drug candidates is unanticipated toxicity, such as cardiotoxicity,
hepatotoxicity, and neurotoxicity, with up to one-third of drug
failures due to cardiotoxicity alone (Cso¨bo¨nyeiova´ et al., 2016).
Thus, there is a need for improved, clinically predictive assays.
Leveraging iPSC-derived cells to develop cell-based in vitro as-
says for predictive safety assessment offers the potential to
deliver higher-throughput, physiologically relevant cell-based
assays to interrogate a range of key tissue-specific toxicities
earlier and at reduced cost to industry-standard preclinical ani-
mal models.
Taking a step towardmore predictive cardiotoxicity assays, an
HTS protocol assessed the effects of 21 FDA-approved anti-
cancer tyrosine kinase inhibitors (TKIs), known to possess
cardiovascular side effects, on viability, contractility, electro-
physiology, calcium handling, and signaling of hiPSC-derived
cardiomyocytes, endothelial cells, and cardiac fibroblasts,
generated from 11 healthy individuals and 2 patients (Sharma
et al., 2017). Vascular endothelial growth factor receptor
2/platelet-derived growth factor receptor-inhibiting TKIs caused
a compensatory increase in cardioprotective insulin and insulin-
like growth factor (IGF) signaling and cardiotoxicity could be
diminished via upregulation of cardioprotective signaling with
exogenous insulin or IGF1.
More complex toxicity models allow modeling of multiorgan
interactions. Since induction of cardiotoxicity or hepatotoxicity
often occurs by way of a cascade of mechanisms in different
tissues, simultaneous detection of different phenotypes through
multimodal combination of high-content screens in different
tissues is required to ensure that tissue- and pathway-specific
effects of compounds can be captured. Using hiPSC-derived
cardiomyocytes and hepatocytes, various high-content and
molecular assay combinations provided simultaneous insight
into cell viability, mitochondrial integrity, and formation of reac-
tive oxygen species (Grimm et al., 2015). For cardiomyocytes,
calcium flux measurements to test effects on beat frequency
were combinedwith competitive ELISA to determine intracellular
cyclic AMP (cAMP) levels as indicator of G protein-coupled
receptor activation and to assess induction of chronotropic
effects. For hepatocytes, high-content imaging was used
to assess cytoskeletal integrity and lipid accumulation as
an indicator of hepatocellular steatosis. Another study with
hiPSC-derived hepatocytes evaluated various assays and
phenotypic markers, including cell viability, nuclear shape,
average and integrated cell area, mitochondrial membrane po-
tential, phospholipid accumulation, cytoskeleton integrity, and
apoptosis, for assessing multiparametric readouts of general‘‘Stem Cells Open up New Opportunities for Disease Modeling and
unit associated protein 1 like 1; Fmr1, fragile Xmental retardation 1; HCS, high-
luripotent stem cell; LOPAC, Library of Pharmacologically Active Compounds;
cleases.




















Figure 2. Schematic Outline of Neurotoxicity Study by Pei et al.
The NTP 80-compound library was screened with isogenic cells at four neural differentiation stages (iPSCs, neural stem cells [NSCs], neurons, astrocytes) using
the MTT assay. Lineage-specific luciferase reporter iPSC lines were used to simplify the neurotoxicity readout (Pei et al., 2016).
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automated high-content screening (HCS) combined general
toxicity assessment by the multi-dye assay with a mechanism-
specific assay using the mitochondrial JC-10 dye to screen the
240-compound Screen-Well Hepatotoxicity Library. These mul-
tiparametric HCS for quantitative in vitro profiling of cardiotoxic-
ity and hepatotoxicity provide both descriptive and mechanistic
toxicity data in a time- and resource-saving format.
In a comparative cytotoxicity assay, the NTP 80-compound
library including drugs, pesticides, and environmental com-
pounds, 37 of which possess reported developmental neurotox-
icity and/or neurotoxicity, was tested on isogenic cells at four
stages of neural differentiation (hiPSCs, neural stem cells, neu-
rons, and astrocytes) (Figure 2). The screen used the MTT assay
(Pei et al., 2016) and identified 50 compounds that significantly
induced cell-type-specific neurotoxicity. The neurotoxicity assay
could be simplified by measuring luciferase activity in lineage-
specific luciferase reporter iPSC lines. To distinguish between
chemically induced specific effects on neurite outgrowth and
nonspecific cytotoxicity, the same compound library was inves-
tigated in a high-throughput, high-content screen with hiPSC-
derived neurons via quantification of total neurite outgrowth,
branches, and processes as well as cell viability (Ryan et al.,
2016). Sixteen out of 38 active compounds showed selective
inhibition of neurite outgrowth, and only for 6 of these 16 com-
pounds could the selectivity be reproduced in a repeat experi-
ment with larger sample size. However, neurite outgrowth is
only one of multiple mechanisms of developmental neurotoxicity
and general neurotoxicity, necessitating other assays to cover
diverse toxic effects on the nervous system.
Challenges of Stem Cell-Based PTS in 2D Cultures
Despite all enthusiasm, however, challenges remain. Stem cells
in culture tend to form heterogeneous populations during differ-
entiation, an outcome that can affect statistical metrics of HTS
campaigns (Kaufmann et al., 2015). Therefore, differentiation
protocols need further optimization to improve efficiency, repro-
ducibility, and eliminate heterogeneity in terms of cell-type-spe-
cific differentiation, biomarker expression, and features that
determine HTS compatibility (Calder et al., 2015; Hoing et al.,
2012). hiPSCs and derived cell lines exhibit variable properties
depending on the cell type of origin (Luu et al., 2018). This vari-
ability contributes significantly to the observed lack of reproduc-
ibility of results among studies. Furthermore, accuracy and6 Cell Chemical Biology 26, August 15, 2019completeness of stem cell differentiation need to be determined
and carefully controlled. Typically, phenotypes are defined by
biomarker patterns (protein or mRNA), the definition of which
can be inconsistent between groups of researchers, leading to
accepted patterns changing over time. Rigorous use of iPSC
technologies will require tighter and more broadly accepted def-
initions of iPSC-derived phenotypes used in screening cam-
paigns. Based on these tighter definitions, selection protocols
can be refined to select specific cell subpopulations from cell
mixtures with varying degrees of maturity or functionally distinct
cell-type-specific properties. These measures will help address
heterogeneity issues and improve accuracy as well as biological
relevance of screening results (Charwat et al., 2015; Steinbeck
et al., 2016; Xu et al., 2016). Consequently, high-throughput fluo-
rescence-activated cell sorting and mass spectrometry analysis
are increasingly used in HTS workflows for extraction of quanti-
tative information (Ding et al., 2018; Edwards and Sklar, 2015;
Zhou et al., 2016).
Stem cell differentiation protocols often require several days
to weeks, and even months, for the generation of desired cell
types. Long protocol durations drive up cost and complexity
of stem cell-based screening campaigns. Although much
progress has been made (Heilker et al., 2014; Qi et al.,
2017), differentiation protocols need further improvement to
reduce the overall duration of differentiation from months to
days. One option is predifferentiating stem cells into highly
specialized precursor cells, such as neural precursors, to
further reduce the time to generate the desired somatic cells
as well as the cost (Reinhardt et al., 2013). Another advantage
of tissue-restricted multipotent precursor cells is that they can
give rise to only a more limited subset of cell types, further
reducing potential heterogeneity among differentiated cells.
In summary, iPSC technologies may solve key issues of PTS:
they provide patient-derived material, allow generation of scarce
or postmitotic cells, facilitate genetic engineering, and hence
allow the use of isogenic cell lines for screening. However,
they still need optimization to reduce heterogeneity, protocol
cost, and duration, and more stringently defined cell-type-
specific biomarkers as broadly accepted consensus among
researchers in industry and academia. Lastly, iPSCs can rarely
be differentiated into cells that resemble an adult phenotype
and thus, maturation protocols need to be developed that
address this issue. Currently employed HTS models cannot yet
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organism, but efforts are starting to approach recreating hetero-
geneous, multicellular biologies in vitro.
Advanced Tissue Culture Methods Allow More
Complexity and Greater Control in Phenotypic
Disease Models
Advantages and Challenges of Next-Generation
Screening Approaches
The ultimate clinical success of PTS hinges on the ability of
in vitro systems to replicate relevant physiological processes
contributing to health and disease in vivo. The multifactorial na-
ture of many diseases has so far prevented addressing them in
straightforward 2D PTS. Tackling novel diseases may require
integrative solutions for modeling cells, tissues, organs, and
pathogens in vitro that act in concert to bring about disease
states. Basic research has been developing and refining tech-
niques such as microfluidics, 3D/organoid cell culture, and or-
gans-on-a-chip, which can mimic ever more complex biological
processes in vitro. These next-generation screening approaches
can combine several organotypic cell types in a more tissue-like
configuration to emulate physiologically interdependent cell
populations as relevant functional screening units in 3D and
over time. Adapting these technologies at their current proof-
of-principle state for industrial high-throughput workflows
represents a new generation of scalable biological screening
approaches for narrowing the gap between in vitro and in vivo
scenarios (Takebe et al., 2017b).
Despite their promise, however, these technologies have so
far not found widespread adoption in large pharmacological
screening campaigns, and the relevance of 3D models remains
yet to be rigorously ascertained. More complex diseasemodels
require more sophisticated and multifaceted cell culture and
readout systems, each with its own set of issues, compounding
difficulties. Thus, the principal challenge lies in the functional
convergence of disparate fields in settings that foster the inter-
action of experts from each discipline, while providing funding
to push through initial challenges. Once achieved, this integra-
tive approach may allow the industrialization of complex
cell-based models to power the next generation of drug
discovery.
3D Tissue Culture and Organoid Technology
Bioactive small molecules are often identified in biological
formats that are cultured as monolayers on 2D surfaces.
These setups facilitate downstream analysis but show little
resemblance to in vivo conditions. Over the past few years,
easy access to hiPSCs has enabled the assembly of de novo
prototissues in the form of organoids (Clevers, 2016; Eisenstein,
2018; Pasca, 2018), and protocols have been developed for
growing 3D aggregates that bear major hallmarks of many tis-
sues (Huch et al., 2017; Lancaster and Knoblich, 2014; Luo
et al., 2016; Qian et al., 2016). As the cellular niche governs
cell behavior (Murrow et al., 2017), it is not surprising that
many features of developmental biology manifest only in 3D cul-
tures (Centeno et al., 2018; Gibbons, 2017; Lancaster et al.,
2013; Passier et al., 2016). Thus, hiPSC-based 3D organoid cul-
tures may provide a more biomimetic 3D tissue-like context for
cells in drug discovery campaigns (Bershteyn and Kriegstein,2013; Mills et al., 2017), reviewed in (Dutta et al., 2017; Fang
and Eglen, 2017; Ho et al., 2018).
First reports toward using organoid technologies for the devel-
opment of HTS approaches in 3D tissue culture are starting to
show both the feasibility of this approach as well as highlight
the challenges before this technology can mature (Fatehullah
et al., 2016). Screening campaigns for cancer therapeutics are
already in use for testing the efficacy of various chemotherapeu-
tics against numerous tumor tissues (Drost and Clevers, 2018),
as tumor size can be easily measured with current assay readout
technologies. In addition, more sophisticated readouts are start-
ing to emerge (Bian et al., 2018; Czerniecki et al., 2018; Vergara
et al., 2017; Zhang et al., 2017). Small-scale toxicity studies in 3D
promise more physiologically relevant results. For example, a
cardiac microphysiological system was developed that allows
culture of viable and functional hiPSC-derived cardiomyocytes
in an aligned 3D m-tissue over multiple weeks and offers multiple
modes of analysis (e.g., biological, electrophysiological, and
physiological) (Mathur et al., 2015). Better consistency of half
maximal effective concentration/half maximal inhibitory concen-
tration values of four model drugs with data obtained from
tissue-scale compared with cellular-scale studies suggests a
significant improvement to predict drug efficacy and toxicity
in vitro.
However, small-molecule screening with more complex 3D
cell assemblies has not yet reached its full potential, as it adds
another layer of complexity on top of the challenges of hiPSC-
based screening (Arlotta, 2018; Horman et al., 2015; Moffat
et al., 2014). Industrial implementation requires extreme repro-
ducibility and efficient, automated workflows to leverage the
economy of scale. Formation of organoids relies to a significant
extent on spontaneous self-organization of hiPSCs into complex
tissues (Di Lullo and Kriegstein, 2017). This process occurs
inherently at random and produces an even higher degree of het-
erogeneity than most advanced protocols in 2D culture. Also,
most organoid workflows require discarding a significant portion
of the resulting aggregates because they did not spontaneously
form structures of interest. Most organoid work to date shows
data that have been generated from samples that have under-
gone a rigorous manual cascade of selections. If organoid ap-
proaches are to be adopted in screening workflows, they need
to become robust enough to self-organize into well-defined,
homogeneous, reproducible 3D tissues, or screening in quantity
will not be possible. In addition, many standard HTS readout
strategies may not be suitable for use in 3D. For example, it is
difficult to obtain optical readouts in large, often opaque cellular
aggregates, as conventional microscopy cannot fully penetrate
large-scale aggregates. Currently, only easily accessible param-
eters such as aggregate diameter have been measured in HTS
formats, with few exceptions (Czerniecki et al., 2018; Mills
et al., 2017; Takebe et al., 2017a; Vergara et al., 2017). Organoids
are not yet suitable for the fast data acquisition of high-content
live-cell imaging procedures, andmay never be. Therefore, read-
outs either are limited to outer layers of aggregates or require sig-
nificant additional sample processing. Some of these issues are
addressed via tissue-clearing approaches that reduce light
absorbance and scattering in tissues, allowing for the acquisition
of optical readouts at greater depths (reviewed in Richardson
and Lichtman, 2017). Finally, the presence of a large number ofCell Chemical Biology 26, August 15, 2019 7
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ponents impair the diffusion of nutrients, oxygen, and potential
pharmacological drug candidates to the core of the aggregate.
Cells in 3D culture may therefore experience distinct mechanical
and physiological conditions depending on their location within a
cellular aggregate. Part of this issue may be mitigated by the
introduction of blood vessels into various organoid models, the
proof-of-principle of which was recently demonstrated (Wimmer
et al., 2019).
Although 3D cultures conceptually promise to be more physi-
ologically relevant than 2D cultures, solid experimental proof is
scarce, with one study showing a negligible difference between
hepatic 2D and 3D cultures (Sirenko et al., 2016). Reasons for a
lack of data on the relevance of 3D studies may include the
comparatively low number of 3D studies with quantitative/
screening results. Before becoming more established, 3D
culture needs to solve its inherent tendency toward highly
heterogeneous samples, to offer novel HTS-compatible fast
readout technologies, and careful comparison of relevant clinical
biomarkers when compared with existing 2D approaches. Ulti-
mately, the relevance of 3D screening technologies can only
be verified once 3D-generated results can be vetted in the clinic.
However, the potential is enormous. Building organ-like human
tissues for HTS campaigns could help bridge the gap between
human in vitro and in vivo physiology and help cut escalating
costs of current drug development.
Microfluidic Systems
Although organoids add tissue-level complexity over the tradi-
tional 2D monocultures used in screening, microfluidics offer
superior environmental control. Many parameters, such as fluid
flow rates, local mechanical and electrical signals, oxygen and
nutrient levels, and the pattern of enclosed cells can be
controlled accurately and varied independently. The possibility
to add (pulsatile) flow can enhance the differentiation, long-
term survival, and maturity of many cell types (Huh et al.,
2010). Microfluidic experiments are often conducted in small,
transparent architectures, which help reduce reagent volumes
to the microliter- or picoliter range per reaction, while being
able to be read out in real time (Esch et al., 2015; Regnault
et al., 2018). This permits the analysis of disease states that
cannot be addressed in conventional screening setups, for
example the dynamic variation of oxygen tension to invoke
vaso-occlusion in sickle-cell disease (Wood et al., 2012).
Many drug metabolism phenomena only emerge after drugs
interact with several tissues. Organs-on-a-chip can combine
different cell types and configurations under continuous-flow
conditions, cultured in reproducible biological architectures in
micrometer-sized chambers with a defined size and shape (Bha-
tia and Ingber, 2014; Picollet-D’hahan et al., 2017; Rothbauer
et al., 2018; Skardal et al., 2017; Takebe et al., 2017b) (see Fig-
ures 3 and 4). Recent proof-of-principle studies even combine
several organs-on-a-chip to form a ‘‘body-on-a-chip,’’ including
a pumpless 14-chamber multiorgan system representing 13 tis-
sues/organs (Miller and Shuler, 2016). Although these technolo-
gies need to mature further to quantitatively emulate complex
body chemistry interactions, these approaches represent first
and important steps that can provide new approaches for
studying the molecular mechanisms of action and the toxicity8 Cell Chemical Biology 26, August 15, 2019of drugs in a physiologically relevant yet standardized context
(Bhatia and Ingber, 2014; Ronaldson-Bouchard and Vunjak-
Novakovic, 2018).
While cumbersome to design, implement, and troubleshoot,
microfluidics are in principle compatible with HTS workflows,
and may be an option to realize complex biological systems in
screens by driving miniaturization, parallelization of reactions,
and rapid analysis (Jackson and Lu, 2016). The need and ability
to screen more complex biological systems at industry scale is
just emerging, and industry-grade small-molecule screens with
organs-on-a-chip have not yet been reported, in large part due
to several significant challenges that still need to be overcome
(for review, see Starokozhko and Groothuis, 2017). However,
just as microfluidics have started to revolutionize standard lab
techniques such as RT-PCR and the -omics techniques, the abil-
ity to mass-produce microfluidic devices combined with the
economy of scale will make microfluidic devices more attractive
as larger-scale screening systems (Mullard, 2018). Currently, the
simplicity and optimization of large-scale screening workflows
are custom-tailored to 384- and 1,536-well designs, which are
more suited to highly optimized 2D TBS and PTS workflows.
Further development of microfluidic devices offers a path
forward for assay designs that accommodate more complex
biological setups and can help combine emerging techniques
such as 3D culture, 3D bioprinting (Yi et al., 2017), or even
device-less microfluidic designs (Walsh et al., 2017) to
create and analyze spatially defined yet heterogeneous
tissues with the rigor and control required for large-scale
screening setup.
Phenotypic Screens in Advanced Culture Systems
Despite the challenges that remain, several studies have already
outlined the potential of PTS in modeling complex phenotypes
that cannot be adequately demonstrated in other TBS-based or
2Dculturemodels, but canbeaddressedbycombining3Dculture,
microfluidics, and can even model interactions of tissues with
pathogens.
HCS by immunostaining of Zika virus (ZIKV)-infected hiPSC-
derived neural progenitor cells during early human neural tissue
development (Zhou et al., 2017) identified that the FDA-
approved small-molecule drugs, hippeastrine hydrobromide
and amodiaquine dihydrochloride dehydrate, reduced ZIKV E
protein levels. Further investigations showed that hippeastrine
hydrobromide rescued several defects associated with ZIKV
infection in human fetal-like forebrain organoids and in the adult
mouse brain.
A new combinatorial screening approach using iPSC-derived
cardiomyocytes cultured in high-density microbioreactor arrays
discovered small-molecule modulators of cardiomyocyte prolif-
eration (Titmarsh et al., 2016). Using 8,100 individual chambers,
the study investigated four well-established small-molecule
modulators of Wnt, Hedgehog, IGF, and fibroblast growth factor
signaling pathways in a combinatorial fashion. It revealed that
CHIR99021 (a GSK3b inhibitor) is the most potent inducer of
human cardiomyocyte proliferation. These results demonstrate
the power of automation, miniaturization, and parallelization
technologies for future hiPSC-based PTS approaches.
First proof-of-concept studies combining microfluidics and





Figure 3. Schematic Overview of Current and Emerging Phenotypic Screening Strategies and their Main Advantages and Challenges
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(2019), https://doi.org/10.1016/j.chembiol.2019.05.007assessment of neuronal cytotoxicity of potential drugs at early
stages of drug discovery (Nierode et al., 2016). A chip-based
microarray allowed for the combinatorial optimization of culture
conditions in 3D at the nanoliter scale by monitoring cell-specific
marker expression using immunofluorescence. Upon screening
of 24 compounds for cytotoxicity and proliferative effects in un-
differentiated versus differentiating progenitors five compoundswith distinct activities depending on the differentiation status
were identified. Such platforms could be scaled up and used
for larger-scale neurotoxicity screening.
Next-Generation Phenotypic Analyses
With recent progress and a wider application of phenotypic ap-





Figure 4. Schematic Overview of Parameters that Can Be Addressed in Microfluidic Setups
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Pegoraro and Misteli, 2017; Reisen et al., 2015). With automa-
tion, genomic, and imaging capabilities soaring, data storage,
annotation, classification, and analysis form new bottlenecks in
the generation of biological insight. Handling of massive
amounts of multidimensional data to unravel complex depen-
dencies creates a new frontier in screening. Machine learning
algorithms are amenable to integrating complex interrelated
data and extracting relevant parameters from datasets that
are too large to analyze by other means, or in cases where rele-
vant parameters are yet unknown. Rapid advances in machine
learning algorithms and, in particular, deep learning are ex-
pected to advance phenotypic approaches that deconvolve
complex systems after recording large swaths of raw data
without previous knowledge of a target (reviewed in Smith
et al., 2018). The resulting datasets can form the starting point
for systems biology strategies that tackle an increasing array of
parameters and detect interdependencies (Lee and Berg,
2013; Schirle and Jenkins, 2016). The latest-generation
screening approaches allow not only target-agnostic but also
phenotype-agnostic strategies. After collecting a large amount
of in-depth data either by -omics/-sequencing-based tech-
niques, or by high-content imaging, cellular responses may be
clustered into phenotypes after the experiment, and only assem-
bled by machine learning approaches into distinct phenotypes
during the analysis stage. This strategy, coupled with spiking
compound librarieswith substances of known and specific activ-
ity, allows for clustering of cellular behaviors into distinct groups,
even without knowing the molecular pathways involved (cell
painting) (Bray et al., 2016). With a sufficient number of curated
datasets, it will become feasible to predict protein/RNA/com-
pound-based phenotypes (in silico modeling) (Digles et al.,10 Cell Chemical Biology 26, August 15, 20192016). Particularly the possibility to acquire dynamic/longitudinal
datasets in microfluidic formats as part of HTS will require novel
data handling and analysis architectures.
Biologists, statisticians, and software experts need to join
ranks to tackle this new challenge. Tracking datasets for com-
pound libraries across research institutions and correlating
phenotypes acquired by different individuals under different con-
ditions could help turning the vision of in silico modeling into a
reality by distilling core multidimensional phenotypic changes
out of a heterogeneous biological sample space. While we are
not aware of such advances in the stem cell field, innovative ap-
proaches including patient-specific, high-content immunofluo-
rescence-driven approaches in complex co-culture formats
with a cross-patient longitudinal integration of datasets exists
in clinical cancer research, in a technique called pharmacoscopy
(Snijder et al., 2017). With the growing availability of stem cell
banks coupled with in-depth patient records, applying such
comprehensive approaches applied to stem cell screens and
compound libraries will drive additional insight into health, devel-
opmental, and disease aspects across cell lines and patients,
thus further broadening the insight and predictability of pheno-
typic changes in stem cell-based screens.
Novel Approaches to Tissue Maintenance and Repair:
Phenotypic Screens to Direct Cell Fate and Generate
Tissue-Resident Stem Cells
Frequently PTS approaches aim at restoring cell function or sur-
vival of terminally differentiated cells that are already present in
their tissues and do not function properly because of age, injury,
or disease. The co-emergence of the ability to direct cell fate
changes with the ability to create and screen tissues in HTS con-
texts opens up an entirely new purpose for PTS: identification of
Figure 5. Illustration of the Three Reprogramming Concepts: iPSC Reprogramming, Direct Reprogramming, and Direct Conversion
During iPSC reprogramming (1), cells are reset completely back to the pluripotent state via an unstable intermediate state, and then differentiated into various cell
types. During direct reprogramming (2), cells follow the route of iPSC reprogramming up to the unstable intermediate state, but subsequently pass onto a
multipotent state rather than heading all the way back to the pluripotent state. Therefore, direct reprogramming gives rise to only a few specific cell types. During
direct conversion (3), cells undergo transdifferentiation and do not pass through a pluripotent or multipotent state, but stay unipotent, and hence give rise to only
one specific cell type.
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therapeutic strategies could replace damaged or lost cells by
converting tissue-resident somatic cells into their respective
tissue-resident stem cells, which, in turn, regenerate missing
somatic cells locally. This autotherapy approach (Davies et al.,
2015; reviewed in Lumelsky et al., 2018) minimizes potential
complications from allogeneic immune-incompatibility as well
as local tissue damage from cell delivery.
Unfortunately, traditional transcription factor-based lineage
conversion requires genetic manipulation of host tissues
(Gascon et al., 2017; Graf and Enver, 2009; Tsunemoto et al.,
2018), which is technically and ethically challenging. PTS is a
powerful tool to study and evolve cell fate conversion ap-
proaches focusing on small molecules. Insights gained can
help ameliorate duration and efficiency of cell fate conversions
to improve yield and quality of desired cell types, e.g., for use
in disease modeling or autologous cell therapy, as well as to
discover novel direct cell-type conversion protocols for regener-
ative medicine. Current phenotypic screens have great potential
for identifying small molecules that can replace transcription
factors and may be more suitable as therapeutic agents (also
summarized in Table S1).
Before clinical translation of cell conversion approaches can
become clinical reality, several technical and regulatory ad-
vances need to be achieved. Technical limitations include low
conversion efficiency, heterogeneity of resulting cell popula-
tions, and only partial functionality of converted cells. Safety
considerations are paramount with reprogramming techniques
with clinical uses as goal, as for example in tissue-based regen-
erative strategies. The death of a patient in a gene therapy clin-
ical trial and therapy-induced cancers (Wilson, 2009) revealed
an insufficient understanding of clinical safety and suitability of
a radically new therapy approach with unfortunate outcome
that hobbled further progress for the following decade. It is vital
that stem cell-based therapeutic approaches do not suffer thesame fate. Therefore, rigorous safety testing and long-term
studies in animal models are indispensable. All concerns about
regulatory requirements need to be addressed on the way to-
ward safe application of cell fate conversion approaches in the
clinic (Kumar et al., 2017). Even with new tools at hand which
direct conversion of somatic cells, these considerations will likely
impose significant hurdles to be overcome.
Here, we address PTS approaches to identify small mole-
cules that are relevant for two types of cell fate conversion:
(1) direct reprogramming (somatic to multipotent stem or pre-
cursor cells) and (2) direct conversion (somatic to somatic
cells) (see Figure 5). In direct reprogramming, cells do not
retrace the path to pluripotency, but only to a multipotent,
intermediate state, giving rise to a more restricted number of
lineages; and, in direct conversion, cells do not pass through
a pluripotent or multipotent state but stay unipotent and go
through a transdifferentiation process to produce only one
desired cell type (Graf and Enver, 2009). We do not discuss
PTS to direct cell fate toward pluripotency, because pluripo-
tent cells bear a high risk of tumorigenicity, and are thus
less suitable for therapeutic approaches.
PTS for Direct Reprogramming Factors––Somatic to
Multipotent Precursors
Direct reprogramming bypasses a potentially tumorigenic
pluripotent state and leads directly to a multipotent stem cell
state. This reduces time and cost spent on reprogramming
and differentiation and lowers the risk of tumor formation by
residual pluripotent cells in clinical applications. These advan-
tages will be beneficial to improve cell supply for disease
modeling as well as regenerative medicine approaches.
Combinatorial PTS has identified a set of nine target-anno-
tated small molecules that were capable of efficiently convert-
ing mouse fibroblasts into tripotent neural stem-like cells
(Zhang et al., 2016a). In another study, human fibroblasts
were converted into cardiomyocyte-like cells by the additionCell Chemical Biology 26, August 15, 2019 11
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transplanted into infarcted mouse hearts, these cells partially
remuscularized the infarcted area. Four small molecules
were shown to be sufficient for reprogramming mouse fibro-
blasts directly into highly expandable cardiovascular
progenitor cells that robustly differentiated into cardiovascular
cells in vitro as well as in vivo in the diseased heart, improving
cardiac function for up to 12 weeks after transplantation
(Zhang et al., 2016b).
An emerging concept that bypasses pluripotency altogether
is the generation of an extraembryonic endoderm XEN-like
state. Cells in the XEN-like state are highly expandable and
shown to be present during the chemical reprogramming of
mouse somatic cells into pluripotent stem cells (Zhao et al.,
2015). Instead of inducing a pluripotent state (and then gener-
ating a somatic state after cellular differentiation), a method
was developed for directly obtaining functional mouse neurons
and hepatocytes via this chemically induced XEN-like state (Li
et al., 2017).
PTS for Direct Conversion Factors––Somatic to Somatic
Direct conversion represents a special subcategory of cell
fate switching. Directly converted cells retain epigenetic
information and aging signatures of the donor cell type,
whereas iPSC-derived cell types exhibit features of rejuvena-
tion, as they are epigenetically reset during iPSC repro-
gramming (Mertens et al., 2015). Thus, direct conversion
technologies open up the investigation of age-related disor-
ders to the realm of HTS. In addition, opposed to direct
reprogramming, direct conversion is faster, has improved effi-
ciency, avoids pluripotency-associated risks of tumorigenesis,
and promises potential use in autologous cell therapies and
autotherapy. Further research and safety testing are needed
to investigate which approaches will be most promising for
clinical applications.
Transcription factor-mediated transdifferentiation of mouse
cardiac fibroblasts into cardiomyocyte-like cells can be greatly
enhanced by the addition of SB431542 (transforming growth
factor b [TGF-b] inhibitor) and XAV939 (Wnt inhibitor). The addi-
tion increases conversion efficiency by 8-fold and shortens
the conversion process from 6 to 8 weeks to only 1 week (Mo-
hamed et al., 2017). Notably, this combinatorial treatment
significantly improves transdifferentiation in vivo and results in
enhanced cardiac function after myocardial infarction. Also,
the efficiency and speed of human cardiac reprogramming
was enhanced in the presence of TGF-b and Wnt inhibitors,
which reduced the number of required transcription factors
from seven to four (Gata4, Mef2c, Tbx5, and myocardin)––
compared with three (Gata4, Mef2c, and Tbx5) in mice. In addi-
tion, efficiency of direct neural conversion of human fibroblasts
was reportedly increased by more than 6-fold by addition of
a six-compound mixture comprising kenpaullone (Gsk3b
inhibitor), prostaglandin E2 (cAMP/PKA modulator), forskolin
(adenylyl cyclase activator), BML210 (HDAC inhibitor), amino-
resveratolsulfat (SIRT1 activator), and PP2 (Src kinase inhibitor)
(Pfisterer et al., 2016).
Furthermore, a small-molecule approach led to the efficient
conversion of human fibroblasts into functional Schwann cells
under chemically defined conditions (Thoma et al., 2014). PTS
for molecules that drive in vivo conversion of mouse myoblasts12 Cell Chemical Biology 26, August 15, 2019into brown-like adipocytes yielded the retinoid X receptor
(RXR) agonist bexarotene, which enhanced mass as well as
function of brown adipose tissue in mice, further establishing
selective RXR activation as a potential therapeutic approach
for the manipulation of brown/beige fat tissue metabolism in vivo
(Nie et al., 2017).
Transdifferentiation also plays a critical role in cardiac fibrosis,
a process whereby large amounts of connective tissue accumu-
late upon physical damage and/or inflammatory insult leading to
organ malfunction and death. A key aspect of fibrosis is the
accumulation of extracellular matrix-secreting activated myofi-
broblasts. Search for ways to inhibit this process led to the
development of a live-cell imaging assay for HTS with primary
rat hepatic stellate cells and to the subsequent discovery of anti-
fibrotic agent CBR-096-4, which exhibited excellent activity in
rodent and human models of lung, liver, as well as skin fibrosis
(Bollong et al., 2017).
Challenges to Overcome for Adaptation of
Next-Generation Screening Approaches
With the current state of screening able to coopt and integrate a
number of novel technologies to allow modeling more complex
diseases, many challenges remain that we summarize here:
d Biology
d To foster biological reproducibility among batches and cell
lines and compatibility of results across different labora-
tories, the outcomes of cell conversion protocols (differen-
tiation and dedifferentiation) need to be better defined
across different laboratories and fields. For example, one
needs to have a global, marker-independent metric such
as an RNA sequencing-based score that determines how
much a given cell resembles a hepatocyte. Each commu-
nity could define several key phenotypes that would help
group and compare results.
d Firm global cell-type definitionswill also help to unify and to
understand the degree of cellular maturation of iPSC-
derived cell types across different laboratories. In turn,
this could help recognize and develop novel ways to
advance aging in screening environments, or, in the case
of direct conversion, to score individual age characteristics
of cells slated for screening. Without a common metric,
findings of age-related phenotypes remain largely incom-
parable between studies.
d Analysis
d Increasing opportunities in datamining require streamlined
software and hardware solutions that can handle large-
scale multifactorial datasets during acquisition and anal-
ysis. Connections between large and diverse types of
data can only be found if they are accessible to a single
analysis platform. New endeavors need to plan for hard-
ware and software that can store and serve disparate
types of data all relating to individual samples and condi-
tions, which can then be analyzed by a unified neuronal
network or other central platform with a holistic data anal-
ysis capability.
d Machine learning and artificial intelligence approaches
need to be integrated into existing analysis pipelines.
Multifactorial datasets increasingly exceed the capacity
Figure 6. Comparison of Conventional and Next-Generation Drug Discovery and Development Pipelines
As next-generation strategies mature, preclinical animal experiments can be phased out.
Cell Chemical Biology
Review
Please cite this article in press as: Friese et al., The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery, Cell Chemical Biology
(2019), https://doi.org/10.1016/j.chembiol.2019.05.007of human-based approaches to extract relevant connec-
tions. Unsupervised methods could form a first frontier of
data sorting, predigesting complex datasets to be then
screened by humans or human-supervised algorithms.
d Machine learning, especially deep neural networks, need
to be developed to deal with the increased demands of
image/data segmentation originating in next-generation
3D multitissue screens. These nonlinear methods could
allow access to morphologically parse image sets that
so far are not digestible by conventional image analysis
methods.
d Automation/Engineering
d Highly manual approaches such as organoid protocols
need to be standardized, automated, and rendered robust
enough to function in high-throughput settings. So far, pro-
tocols relying on self-organizing tissues do not meet the
rigorous standards of reproducibility required for large-
scale screening. Outcomes need to be measured on a
standardized global metric, see argument above.
d Microfluidics need to become robust enough to be paral-
lelized in massive screening workflows. Issues such as
expensive low-volume production, cumbersome assem-
bly, and lack of standardization, need to be addressed in
order to generate cost-effective microfluidic solutions
based on the economy of scale.
d Ultimately, engineering and automation must drop the
costs for complex cellular models while minimizing any
manual intervention. Cell seeding, maintenance, anal-ysis, and disposal all need to be able to be handled in
a system that can process thousands of samples in
parallel in a standardized format. Microfluidics holds
the promise to provide these characteristics but have
not yet passed the proof-of-principle stage in academic
environments.
d Overall
d Next-generation screening technologies including 3D cul-
ture and microfluidic approaches will need to be validated
in comparison with existing 2D approaches in the clinic to
gain widespread acceptance.Outlook
Over the past decade, hiPSC-based PTS technologies have
matured and proven to integrate well with the HTS drug dis-
covery workflows. More complex biological systems require
the convergence of more sophisticated cell culture techniques
(3D and microfluidics), automation, and analysis methods. For
a number of proof-of-principle studies, this has already been
achieved. However, transfer to industry scale systems still re-
quires further development to achieve efficient scalability for
testing large compound libraries in next-generation phenotypic
formats in a robust and cost-efficient manner.
Given their complexity, we expect that next-generation
screening approaches will complement rather than replace con-
ventional TBS approaches for primary screens. But we envision
that 3D phenotypic assay technologies, including organoids and
organs-on-a-chip, or even bodies-on-a-chip (see Figure 6), willCell Chemical Biology 26, August 15, 2019 13
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integrated and sophisticated models combining organoids,
sensors, and microfluidics are already taking shape (Zhang
et al., 2017).
PTS is on the rise again as a technology for identification
of bioactive compounds. Different fields are coalescing, bringing
together iPSC technology, organoids, microfluidics, and ad-
vanced analysis pipelines for big data projects. Collaborative ef-
forts are therefore indispensable for achieving interdisciplinary
solutions involving experts in chemical biology and medicinal
chemistry (Kapoor et al., 2016; Plowright et al., 2017) for exploit-
ing the full potential of small-molecule iPSC-based PTS espe-
cially in the pharmaceutical industry (see Figure 1; for examples,
see Plowright et al., 2017; Haasen et al., 2017; Ursu et al., 2017).
For each individual indication, the stem cell community needs to
improve stem cell tissue culture to advance and expand the dis-
ease model portfolio and organoid technologies in close collab-
oration with clinicians and experts in human disease physiology
to better approximate the in vitro with the in vivo models. This
outcome cannot be achieved without engineers providing scal-
able, tunable, and cheaper automated workflow solutions and
microfluidic devices that are suitable for large-scale screening
campaigns. The chemical biology community needs to develop
strategies for target deconvolution of large datasets from com-
plex biological samples involving advanced systems biology
strategies as well as machine learning algorithms. In addition,
these groups need to interact with experts in disease biology
for individual indications. These challenges will be efficiently
solved in interdisciplinary academic-corporate partnerships
and translational research centers in an open innovation fashion.
The synergies created will facilitate the development of more
specific and efficient methods for assessing the effects of dis-
eases and drugs in vitro and open up new avenues for treating
many afflictions that are beyond our reach today.
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